Skip to search formSkip to main contentSkip to account menu

Goserelin

Known as: 6-[O-(1,1-Dimethylethyl)-D-serine]-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig) 2-(aminocarbonyl)hydrazide, Goserelin [Chemical/Ingredient], Luteinizing hormone-releasing factor (pig), 6-(O-(1,1-dimethylethyl)-D-serine)-10-deglycinamide-, 2-(aminocarbonyl)hydrazide 
A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates… 
National Institutes of Health

Related topics

Related topics

15 relations

Broader (1)

Antineoplastic Agents, Hormonal
Goserelin 10.8 MG Drug Implant [Zoladex]In BloodNCIt Antineoplastic Agent Terminologyagonists

Narrower (3)

Goserelin AcetateICI-118630Zoladex

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Tailored protein release from biodegradable poly(ε-caprolactone-PEG)-b-poly(ε-caprolactone) multiblock-copolymer implants.
Highly Cited
2009
Highly Cited
2009
Twenty‐four‐month postradiation prostate biopsies are strongly predictive of 7‐year disease‐free survival
The objective of this study was to evaluate the predictive value of prostate biopsies that were obtained 24 months after the… 
2003
2003
Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.
2003
2003
Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer.
2000
2000
Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer--self-rated physiological effects and symptoms.
After primary surgery, 149 premenopausal breast cancer patients, with node-negative disease, were randomized to one of four… 
1999
1999
Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer
The high potency and selectivity of new aromatase inhibitors has translated to greater efficacy and improved tolerability in… 
Review
1997
Review
1997
The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.
Highly Cited
1996
Highly Cited
1996
The effects of the gonadotrophin releasing hormone analogue (goserelin) and prostaglandin E1 (misoprostol) on cervical resistance prior to transcervical resection of the endometrium
References 1 Melin P. Oxytocin antagonists in preterm labour and delivery. Baillieres Clin Obstet Gynaecol 1993; 7 : 577-600. 2… 
Review
1992
Review
1992
Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients
Highly Cited
1989
Highly Cited
1989
Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
One hundred thirty-four pre- and perimenopausal patients presenting with metastatic breast cancer (median age, 42 years; range… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)